Health ❯ Healthcare ❯ Regulatory Affairs

European Medicines Agency

Drug Approval Process Marketing Authorization Drug Safety Orphan Medicinal Products CHMP Opinion Approval Process CHMP Review Process Drug Reviews Drug Regulation

EMA Panel Recommends Rejecting Rezurock for Chronic Graft-Versus-Host Disease in EU

Regulators cited limited, non-comparative evidence and the lack of new efficacy data before 2030 as key reasons for the negative view.

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy